侵及喉及消化道的结外鼻型NK/T细胞淋巴瘤1例并文献复习

马思捷; 陈兴健; 刘增平; 郭玉芬

doi:10.13201/j.issn.2096-7993.2023.11.012

侵及喉及消化道的结外鼻型NK/T细胞淋巴瘤1例并文献复习

- 兰州大学第二医院耳鼻咽喉头颈外科(兰州，730030)

详细信息

通讯作者: 郭玉芬，E-mail: guoyflz@163.com

中图分类号: R322.3

收稿日期: 2022-01-17

刊出日期: 2023-11-03

Extranodal NK/T cell lymphoma, nasal type involving the larynx and digestive tract: a case report and literature review

- Department of Otolaryngology, Head and Neck Surgery, Lanzhou University Second Hospital, Lanzhou, 730030, China

More Information

Corresponding author: GUO Yufen, E-mail: guoyflz@163.com

Received Date: 17 January 2022

Publish Date: 03 November 2023

摘要

摘要: 结外鼻型NK/T细胞淋巴瘤(extranodal NK/T cell lymphoma，nasal type，ENKTL)是NK细胞起源的高度侵袭性恶性肿瘤，本文报告1例侵及喉及消化道的ENKTL患者，临床表现为声音嘶哑、鼻腔内肿物。
- 结外鼻型NK/T细胞淋巴瘤 /
- 喉 /
- 消化道
Abstract: Extranodal NK/T cell lymphoma, nasal type(ENKTL) is a highly aggressive malignant tumor derived from NK cells. This article reports a case of ENKTL invading the larynx and digestive tract. The clinical clinical manifestations include hoarseness and intranasal masses.
- extranodal NK/T cell lymphoma, nasal type /
- larynx /
- digestive tract

HTML全文

图 1 术前电子喉镜检查

下载: 全尺寸图片幻灯片

图 2 右侧人中嵴旁病损

下载: 全尺寸图片幻灯片

图 3 副鼻窦CT

下载: 全尺寸图片幻灯片

图 4 鼻部及喉部病损组织病理像

下载: 全尺寸图片幻灯片

图 5 第4疗程大评估时复查电子喉镜

下载: 全尺寸图片幻灯片

图 6 第3疗程化疗后行肠镜检查

下载: 全尺寸图片幻灯片

参考文献(16)

[1]	李兰, 杨道科, 郎锦义, 等. 1例肺原发性结外鼻型NK/T细胞淋巴瘤的临床分析[J]. 中国癌症杂志, 2019, 21(1): 57-62. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201901011.htm
[2]	Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas[J]. J Hematol Oncol, 2017, 10(1): 85. doi: 10.1186/s13045-017-0452-9
[3]	McBride P. Photographs of a case of rapid destruction of the nose and face. 1897[J]. J Laryngol Otol, 1991, 105(12): 1120. doi: 10.1017/S0022215100118407
[4]	Lisowska G, Zięba N, Stryjewska-Makuch G, et al. Natural Killer(NK)//T-Cell Lymphoma, Nasal Type, with Periorbital Involvement: A Case Report and Literature Review[J]. Am J Case Rep, 2020, 21: e926599.
[5]	Taali L, Abou-Elfadl M, Fassih M, et al. Nasal NK/T-cell lymphoma: A tragic case[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2017, 134(2): 121-122. doi: 10.1016/j.anorl.2016.08.006
[6]	张迎宏, 段清川, 左强. 15例鼻腔鼻窦非霍奇金淋巴瘤患者的临床特征分析[J]. 临床耳鼻咽喉头颈外科杂志, 2017, 31(21): 1653-1657. https://lceh.whuhzzs.com/article/doi/10.13201/j.issn.1001-1781.2017.21.008
[7]	于刚, 崔潇, 王铮, 等. 咽喉部淋巴瘤的临床分析[J]. 中国耳鼻咽喉颅底外科杂志, 2016, 22(5): 388-392. https://www.cnki.com.cn/Article/CJFDTOTAL-ZEBY201605014.htm
[8]	Gao C, Liu JL, Zhang MN, et al. Primary extrasensal nasal-type natural killer/T-cell lymphoma of the sigmoid colon and leocecal junction: A case report[J]. Turk J Gastroenterol, 2020, 31(12): 955-956.
[9]	范盼红, 龚智泉, 贾琳娇, 等. 消化系统原发结外鼻型NK/T细胞淋巴瘤13例临床病理特征分析[J]. 中华病理学杂志, 2021, 50(10): 1122-1127. doi: 10.3760/cma.j.cn112151-20210304-00186
[10]	Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells[J]. Cancer, 1995, 76(11): 2351-2356. doi: 10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1
[11]	Lee SH, Ahn YC, Kim WS, et al. The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma[J]. Haematologica, 2006, 91(3): 427-428.
[12]	Jeong SH. Extranodal NK/T cell lymphoma[J]. Blood Res, 2020, 55(S1): S63-S71.
[13]	中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(7): 707-735. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYX202301001.htm
[14]	Lapeña-Rodríguez M, Garcés-Albir M, Gadea-Mateo R, et al. Multiple small bowel perforations during the treatment of primary intestinal extranodal natural killer/T-cell lymphoma, nasal type[J]. Br J Haematol, 2021, 193(5): e39-e42.
[15]	Akbar M, Clasen-Linde E, Specht L. Extranodal NK/T-cell lymphoma, nasal type, with extranasal presentation-a case report and a review of the literature[J]. Acta Oncol, 2020, 59(12): 1480-1487.
[16]	Zhu SY, Yuan Y, Liu K, et al. Primary NK/T-cell lymphoma of the larynx: Report of 2 cases and review of the English-, Japanese-, and Chinese-language literature[J]. Ear Nose Throat J, 2016, 95(4-5): E1-8.